Aclys Bio discovers and develops precision biologics for the treatment of cancer. Aclys has identified a set of novel precision and immune-oncology targets from the tumor molecular profiles of tens of thousands of cancer patients and is building antibody-based therapies against each target, both for internal development, and for partnership. Aclys’s Precision ImmunoLogical Antibody™ discovery platform (PILA™ or PILA Platform™) enables Aclys’s rapid antibody engineering and optimization and evaluation. The resultant new class of highly developable precision biologics has unique potential to decrease clinical trial times, costs, and risk, while improving trial success rates and ultimately, patient lives.

Aclys Bio discovers and develops precision biologics for the treatment of cancer.

Get started